Sugi Predict

Sugi Predict / Compounds / SCHEMBL2459477

SCHEMBL2459477

SCHEMBL2459477

NC(=O)c1cccc(C2=C3C=NC=C[N+]3(N)C(c3cccc(OCc4ccccc4)c3)=N2)c1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MRGPRX4 Q96LA9 2/20 0.43
▸ NR4A2 P43354 2/20 0.42
▸ NR1H4 Q96RI1 1/20 0.41
▸ MAOB P27338 1/20 0.40
▸ PARP10 Q53GL7 1/20 0.40
▸ CHEK2 O96017 1/20 0.40
▸ SMPD1 P17405 2/20 0.39
▸ SRD5A2 P31213 1/20 0.39
▸ PTPN1 P18031 1/20 0.38
▸ FAAH O00519 1/20 0.38
▸ SPHK2 Q9NRA0 2/20 0.38
▸ GPR132 Q9UNW8 1/20 0.37
▸ SIRT2 Q8IXJ6 1/20 0.37
▸ DHODH Q02127 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2460199 0.93 PARP10 (0.45) MRGPRX4NR4A2MAOBPARP10CHEK2
SCHEMBL2460398 0.89 MAOB (0.41) MRGPRX4NR4A2MAOBDHODH
SCHEMBL2459704 0.87 TSHR (0.39) MRGPRX4NR4A2MAOBDHODH
SCHEMBL2460166 0.86 MRGPRX4 (0.42) MRGPRX4NR4A2MAOBPARP10
SCHEMBL2460148 0.86 CFD (0.42) MRGPRX4NR4A2MAOBSPHK2
SCHEMBL3537676 0.86 MRGPRX4 (0.42) MRGPRX4NR4A2NR1H4MAOBPARP10
SCHEMBL2462894 0.85 ALOX5 (0.41) MAOBDHODH
SCHEMBL4352476 0.84 PARP10 (0.42) PARP10CHEK2
SCHEMBL3537072 0.82 MAOB (0.40) MRGPRX4NR4A2MAOBDHODH
SCHEMBL2459648 0.82 MRGPRX4 (0.50) MRGPRX4NR4A2NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 — — EP claimed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 — — US claimed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 — — US claimed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 — — US claimed
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 — — EP disclosed
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-07-16 — — US disclosed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 — — US disclosed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 — — US disclosed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS IGF1R, IRS1, IGFBP1 MRGPRX4 1767/4885NR4A2 1075/4885NR1H4 3507/4885
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors IGF1R, IRS1, IGFBP1 MRGPRX4 1767/4885NR4A2 1075/4885NR1H4 3507/4885
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors IGF1R, IRS1, IGFBP1 MRGPRX4 1767/4885NR4A2 1075/4885NR1H4 3507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.